Laval, Quebec, Canada-based Valeant Pharmaceuticals' new CFO Paul S. Herendeen will receive a base salary of $1 million and is eligible for an additional bonus as high as $2.4 million, according to The Wall Street Journal.
Mr. Herendeen joined Valeant from Florham Park, N.J.-based Zoetis, a global animal health company. Under his deal with Valeant, Mr. Herendeen will also get $10 million in cash to compensate him for equity compensation he gave up when he left Zoetis, according to the report.
In 2015, Mr. Herendeen's pay totaled $630,000 as executive vice president and CFO of Zoetis. He also received a $595,350 bonus last year.
More articles on executive compensation:
Mylan execs took large raises amidst EpiPen price spikes
Rate of Mass. hospital executive pay growth eclipses healthcare spending
How did compensation change for executives, providers from 2015 to 2016?